News und Analysen
![Agilent Signs Sponsorship Agreement with My Green Lab](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Agilent Signs Sponsorship Agreement with My Green Lab
Agilent Technologies Inc. (NYSE: A) announced today that it has become a top-level sponsor of My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific
![Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 Pandemic](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 Pandemic
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces the
![Veeva Introduces New Capabilities for Remote Drug Sampling in Veeva CRM Engage Meeting](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Veeva Introduces New Capabilities for Remote Drug Sampling in Veeva CRM Engage Meeting
Veeva Systems (NYSE: VEEV) today introduced new remote sampling capabilities in Veeva CRM Engage Meeting. Remote sampling enables field reps to capture and fulfill healthcare professionals’ (HCPs)
![Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced its 2019 financial
![IMV to Participate in Adelaide Capital’s Virtual COVID & Healthcare Mini Conference](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
IMV to Participate in Adelaide Capital’s Virtual COVID & Healthcare Mini Conference
IMV Inc. (Nasdaq: IMV; TSX: IMV) a clinical-stage biopharmaceutical company, today announced that Company’s management will be participating in Adelaide Capital’s Virtual COVID & Healthcare Mini
![Quidel to Hold First Quarter 2020 Financial Results Conference Call on May 6th, 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Quidel to Hold First Quarter 2020 Financial Results Conference Call on May 6th, 2020
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2020 financial
![Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2020 financial results on Tuesday, May 5, 2020, after the close of the U.S. financial markets. Clovis’ senior management will
![VALBIOTIS veröffentlicht Jahresergebnisse für 2019](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
VALBIOTIS veröffentlicht Jahresergebnisse für 2019
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung
![Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells
Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO)
![4SC: Bald wissen alle mehr!](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
4SC: Bald wissen alle mehr!
Im Rahmen ihrer heute vorgelegten Zwischenmitteilung zum ersten Quartal informiert die Münchner Biotechschmiede 4SC (WKN: A14KL7) über wesentliche Ereignisse und gibt einen Überblick über die
![NANOBIOTIX Provides Updates on Clinical Development Continuity in the Context of the COVID-19 Crisis](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
NANOBIOTIX Provides Updates on Clinical Development Continuity in the Context of the COVID-19 Crisis
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’) today announced updates to the Company’s operational and global development plan in light of the
![VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005949/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
![VALBIOTIS publishes its annual results for 2019](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
VALBIOTIS publishes its annual results for 2019
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005808/en/
Valbiotis pipeline (Photo: Business Wire)
VALBIOTI
![Premier Inc. Real-Time Technology Solution Tracks, Manages and Supports Treatment of COVID-19 Patients Across the Country](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Premier Inc. Real-Time Technology Solution Tracks, Manages and Supports Treatment of COVID-19 Patients Across the Country
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, is marshaling all its data and technology capabilities to provide real-time, integrated solutions that help make it easier for
![Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![Biofrontera: Geschäfte laufen schleppend – das soll nun helfen!](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Biofrontera: Geschäfte laufen schleppend – das soll nun helfen!
Das März-Quartal von Biofrontera (WKN: 604611) war laut am Freitag verkündeter vorläufiger Zahlen wenig überraschend durch die COVID-19-Pandemie bestimmt.
Die negativen Einfüsse spürte der deutsche
![Premier Inc. Survey: Isolation Gowns Replace N95 Masks as the Top Shortage Concern Among Hospitals and Health Systems Treating COVID-19 Patients](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Premier Inc. Survey: Isolation Gowns Replace N95 Masks as the Top Shortage Concern Among Hospitals and Health Systems Treating COVID-19 Patients
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results finding that isolation gowns surpassed N95 masks as the top personal protective equipment (PPE)
![Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. Mr. McClung will
![Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19
Illumina, Inc. (NASDAQ: ILMN) announces the Illumina SARS-CoV-2 Data Toolkit, a new suite of data analysis tools and workflow functionality for researchers working with the virus using
![VALBIOTIS beschleunigt seine klinische Pipeline-Entwicklung im Hinblick auf neue Indikationen: Reduzierung von kardiovaskulären und Lebersteatose-Risiken](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
VALBIOTIS beschleunigt seine klinische Pipeline-Entwicklung im Hinblick auf neue Indikationen: Reduzierung von kardiovaskulären und Lebersteatose-Risiken
VALBIOTIS (Paris: ALVAL) (FR0013254851 – ALVAL / PEA/-KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von
![Chemed To Report First-Quarter 2020 Earnings April 28, Related Conference Call To Be Held On April 29](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Chemed To Report First-Quarter 2020 Earnings April 28, Related Conference Call To Be Held On April 29
Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the first quarter ended March 31, 2020, on Tuesday, April 28, 2020, following the close of trading on the
![Evotec: Neue Knaller-Kooperation](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Evotec: Neue Knaller-Kooperation
Evotec (WKN: 566480) verkündet heute eine strategische Partnerschaft und Beteiligungsvereinbarung mit leon-nanodrugs aus München. Mit der auf Innovation ausgerichteten Zusammenarbeit will Evotec
![Charles River Laboratories Schedules First-Quarter 2020 Earnings Release and Conference Call](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Charles River Laboratories Schedules First-Quarter 2020 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2020 financial results on Thursday, May 7th, before the market opens. A conference call has been scheduled to